✦ LIBER ✦

Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study

✍ Scribed by Moscetti, Luca; Nelli, Fabrizio; Fabbri, Maria A; Sperduti, Isabella; Alesini, Daniele; Cortesi, Enrico; Gemma, Donatello; Gamucci, Teresa; Grande, Roberta; Pavese, Ida; Franco, Daniela; Ruggeri, Enzo M.

Book ID: 120362838
Publisher: Springer US
Year: 2013
Tongue: English
Weight: 233 KB
Volume: 31
Category: Article
ISSN: 0167-6997
DOI: 10.1007/s10637-013-9936-9

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Continuing Single-Agent Bevacizumab as M

Continuing Single-Agent Bevacizumab as Maintenance Therapy After Induction XELOX (or FOLFOX) Plus Bevacizumab in First-Line Treatment of Metastatic Colorectal Cancer

✍ Diaz-Rubio, E.; Pietrantonio, F.; de Braud, F. 📂 Article 📅 2012 🏛 Alphamed Press 🌐 English ⚖ 192 KB

Bevacizumab plus FOLFIRI or FOLFOX in ch

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study

✍ Astrid Lièvre; Emmanuelle Samalin; Emmanuel Mitry; Eric Assenat; Christine Boyer 📂 Article 📅 2009 🏛 BioMed Central 🌐 English ⚖ 588 KB

Multicenter phase II study of second-lin

Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy

✍ Yong Sang Hong, Jeeyun Lee, Kyu-pyo Kim, Jae-Lyun Lee, Young Suk Park, Joon Oh P 📂 Article 📅 2012 🏛 Springer US 🌐 English ⚖ 260 KB

A retrospective observational study on t

A retrospective observational study on the safety and efficacy of first-line treatment with bevacizumab combined with FOLFIRI in metastatic colorectal cancer

✍ López, R; Salgado, M; Reboredo, M; Grande, C; Méndez, J C; Jorge, M; Romero, C; 📂 Article 📅 2010 🏛 Nature Publishing Group 🌐 English ⚖ 320 KB

XELOX and bevacizumab followed by single

XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study

✍ Rosati, Gerardo; Avallone, Antonio; Aprile, Giuseppe; Butera, Alfredo; Reggiardo 📂 Article 📅 2012 🏛 Springer 🌐 English ⚖ 269 KB

Bevacizumab plus chemotherapy as first-l

Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: Results from a large German community-based observational cohort study

✍ Stein, Alexander; Petersen, Volker; Schulze, Mathias; Seraphin, Jörg; Hoeffkes, 📂 Article 📅 2014 🏛 Informa plc 🌐 English ⚖ 406 KB